Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Asenapine Sublingual Tablets, 5 mg and 10 m. The company has enclosed its press release on 11th December 2020 regarding the same.
The above information is a part of company’s filings submitted to BSE.